Stopwatch image

CEQUA provides fast results and continued improvement over
time1,4,5

Review the data and see
how CEQUA gets results in
as little as 2 weeks.4

See fast results
Thumbs up image

Most patients found CEQUA to be comfortable right from the start2,6

95% of patients
experienced no or mild
instillation site pain.1,6,a,b

See safety information
Calendar image

Patients stayed
on CEQUA longer
than Xiidra® or
Restasis®3,c

A real-world analysis compared duration of medications for dry eye disease (DED).

Compare for yourself

CEQUA clinical trial safety

The most common adverse events reported in patients were instillation site pain (22%) and conjunctival hyperemia (6%).7

CEQUA has savings options for all insured patientsd

Learn how to help your patients save

aInstillation site pain included burning and stinging.1,6

bThe first time they tried CEQUA, 9 out of 10 patients reported no or mild discomfort after 3 minutes.2

cCEQUA vs Xiidra showed a numerical difference in time on treatment and persistence. Results were not statistically significant. CEQUA vs Restasis showed a statistically significant difference in time to treatment discontinuation.

dPatients with commercial, Medicare, and other government insurance.

 
 
Indications and Usage

CEQUA® (cyclosporine ophthalmic solution) 0.09% is a calcineurin inhibitor immunosuppressant indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye).

Important Safety Information

WARNINGS AND PRECAUTIONS

Potential for Eye Injury and Contamination: To avoid the potential for eye injury and contamination, advise patients not to touch the vial tip to the eye or other surfaces.

Use with Contact Lenses: CEQUA should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following administration of CEQUA ophthalmic solution.

Adverse Reactions

The most common adverse reactions reported in greater than 5% of patients were pain on instillation of drops (22%) and conjunctival hyperemia (6%). Other adverse reactions reported in 1% to 5% of patients were blepharitis, eye irritation, headache, and urinary tract infection.

Please see the Full Prescribing Information.

 

References: 1. Goldberg DF, Malhotra RP, Schechter BA, Justice A, Weiss SL, Sheppard JD. A phase 3, randomized, double-masked study of OTX-101 ophthalmic solution 0.09% in the treatment of dry eye disease. Ophthalmology. 2019;126(9):1230-1237. 2. Tauber J, Schechter BA, Bacharach J, et al. A phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease. Clin Ophthalmol. 2018;12:1921-1929. 3. Karpecki P, Barghout V, Schenkel B, et al. A retrospective analysis of real-world treatment patterns in patients with dry eye disease receiving CEQUA, Restasis, or Xiidra. Poster presented at AMCP Nexus; October 11-14, 2022; National Harbor, MD. 4. Schechter BA, Urbieta M, Bacharach J, et al. Effect of OTX-101 in patients with dry eye disease at day 14 of treatment: ocular surface endpoint results from the phase 2b/3 clinical trial. Clin Ophthalmol. 2022;16:4145-4151. 5. Malhotra R, Devries DK, Luchs J, et al. Effect of OTX-101, a novel nanomicellar formulation of cyclosporine A, on corneal staining in patients with keratoconjunctivitis sicca: A pooled analysis of phase 2b/3 and phase 3 studies. Cornea. 2019;38:1259-1265. 6. Data on file. Cranbury, NJ: Sun Pharmaceutical Industries, Inc. 7. CEQUA [package insert]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; 2022.

Indications and Usage

CEQUA® (cyclosporine ophthalmic solution) 0.09% is a calcineurin inhibitor immunosuppressant indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye).

Important Safety Information

WARNINGS AND PRECAUTIONS

Potential for Eye Injury and Contamination: To avoid the potential for eye injury and contamination, advise patients not to touch the vial tip to the eye or other surfaces.

Use with Contact Lenses: CEQUA should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following administration of CEQUA ophthalmic solution.

Adverse Reactions

The most common adverse reactions reported in greater than 5% of patients were pain on instillation of drops (22%) and conjunctival hyperemia (6%). Other adverse reactions reported in 1% to 5% of patients were blepharitis, eye irritation, headache, and urinary tract infection.

Please see the Full Prescribing Information.

© 2024 Sun Ophthalmics, a division of Sun Pharmaceutical Industries, Inc. All rights reserved.

CEQUA and NCELL are registered trademarks of Sun Pharmaceutical Industries Limited.

All other trademarks are the property of their respective owners.

PM-US-CQA-1124 07/2024